Flutamide

Spezifikationen

13311-84-7CAS-Nummer

236-341-9EG-Nummer

2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamideIUPAC-Name

C11H11F3N2O3Chemische Formel

276.21 g/molMolekulargewicht

flutamide; 13311-84-7; Eulexin; Niftolide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide; Sch 13521; Drogenil; NFBA; niftolid; Flutamida; Flutamidum; Sch-13521; 4'-Nitro-3'-trifluoromethylisobutyranilide; 2-Methyl-N-(4-nitro-3-[trifluoromethyl]phenyl)propanamide; Eulexine; Propanamide, 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-; SCH13521; DTXSID7032004; alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide; NSC-215876; Propanamide, 2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-; 76W6J0943E; CHEBI:5132; DTXCID9011121; Flutacell; ApoFlutamide; NovoFlutamide; Novo Flutamide; Apo Flutamide; Fluta cell; FlutaGRY; PMS Flutamide; Fluta GRY; 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)propanamide; RefChem:55220; L02BB01; 236-341-9; Euflex; Niftholide; Cebatrol, veterinary; Flutamin; N-(4-NITRO-3-(TRIFLUOROMETHYL)PHENYL)ISOBUTYRAMIDE; MFCD00072009; NSC 215876; CHEMBL806; 4-Nitro-3-(trifluoromethyl)isobutyranilide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propionamide; NCGC00015452-09; Odyne; 4'-Nitro-3'-trifluoromethylisobutyramilide; CAS-13311-84-7; Ham's F-12 medium; Flutamidum [INN-Latin]; Flutamida [INN-Spanish]; Flutamide USP25; N-[4-Nitro-3-(trifluoromethyl)phenyl]isobutyramide; Prostandril; Chimax; .alpha.,.alpha.,.alpha.-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide; SMR000058187; Eulexin (TN); CCRIS 7246; m-Propionotoluidide,.alpha.,.alpha.-trifluoro-; SR-01000075888; EINECS 236-341-9; NK-601; BRN 2157663; .alpha.,.alpha.-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide; m-Propionotoluidide,.alpha.,.alpha.-trifluoro-2-methyl-4'-nitro-; Flutamide CRS; UNII-76W6J0943E; 4'-Nitro-3'-(trifluoromethyl)isobutyranilide; Flutamide [USAN:USP:INN:BAN]; Prestwick_228; Flutamide (Eulexin); Flutamide (Standard); Spectrum_001210; CPD000058187; FLUTAMIDE [INN]; FLUTAMIDE [JAN]; FLUTAMIDE [MI]; FLUTAMIDE [USAN]; Prestwick0_000180; Prestwick1_000180; Prestwick2_000180; Prestwick3_000180; Spectrum2_001201; Spectrum3_001421; Spectrum4_000829; Spectrum5_001450; Lopac-F-9397; F0663; Flutamide (pubertal study); FLUTAMIDE [MART.]; F 9397; FLUTAMIDE [USP-RS]; FLUTAMIDE [WHO-DD]; SCHEMBL3934; Lopac0_000557; BSPBio_000079; BSPBio_003122; KBioGR_001377; KBioSS_001690; MLS000069634; MLS001065596; MLS002548892; DivK1c_000459; SPECTRUM1500995; Flutamide - Bio-X trade mark; SPBio_000982; SPBio_002000; Flutamide (JP18/USP/INN); BPBio1_000087; GTPL6943; orb1226528; orb1310563; FLUTAMIDE [EP IMPURITY]; FLUTAMIDE [ORANGE BOOK]; CHEMBL4759307; FLUTAMIDE [EP MONOGRAPH]; SCHEMBL12932289; SCHEMBL29349783; HMS501G21; HY-B0022R; KBio1_000459; KBio2_001690; KBio2_004258; KBio2_006826; KBio3_002342; FLUTAMIDE [USP MONOGRAPH]; NINDS_000459; GLXC-07722; HMS1568D21; HMS1921O16; HMS2090I18; HMS2092O14; HMS2095D21; HMS2230P19; HMS3259I03; HMS3261P15; HMS3373C12; HMS3655G22; HMS3712D21; HMS5080H03; Pharmakon1600-01500995; HY-B0022; MSK11432; YIA13472; Tox21_110154; Tox21_202169; Tox21_300536; Tox21_500557; BDBM50131270; CCG-39105; EBC-03834; m-Propionotoluidide, 2-methyl-4'-nitro-alpha,alpha,alpha-triflouro-; m-Propionotoluidide, alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro-; NSC147834; NSC215876; NSC757817; s1908; SBB006930; AKOS001025465; AKOS015994751; AKOS025243203; m-Propionotoluidide, .alpha.,.alpha.,.alpha.-trifluoro-2-methyl-4'-nitro-; Tox21_110154_1; AB02835; DB00499; FF23510; KS-5091; LP00557; NC00451; NSC-147834; NSC-757817; SDCCGSBI-0050540.P004; IDI1_000459; NCGC00015452-01; NCGC00015452-02; NCGC00015452-03; NCGC00015452-04; NCGC00015452-05; NCGC00015452-06; NCGC00015452-07; NCGC00015452-08; NCGC00015452-10; NCGC00015452-11; NCGC00015452-12; NCGC00015452-13; NCGC00015452-14; NCGC00015452-15; NCGC00015452-16; NCGC00015452-19; NCGC00015452-20; NCGC00015452-31; NCGC00015452-32; NCGC00091460-01; NCGC00091460-02; NCGC00091460-03; NCGC00091460-04; NCGC00091460-05; NCGC00091460-06; NCGC00091460-07; NCGC00091460-08; NCGC00091460-09; NCGC00254495-01; NCGC00259718-01; NCGC00261242-01; AC-24192; BF166239; ST058409; SY036411; SBI-0050540.P003; DB-042163; 3'-Trifluoromethyl-4'-Nitro-Isobutyranilide; AB00052188; EU-0100557; F4680; NS00002675; SW196536-4; T0489; 4''-nitro-3''-trifluoromethylisobutyranilide; A10796; C07653; D00586; EN300-119548; AB00052188-09; AB00052188_10; AB00052188_11; F358096; Q418669; SR-01000075888-1; SR-01000075888-6; SR-01000075888-7; SR-01000075888-9; BRD-K28307902-001-05-0; BRD-K28307902-001-20-9; BRD-K28307902-001-21-7; Flutamide, certified reference material, TraceCERT(R); Z56755651; Flutamide, European Pharmacopoeia (EP) Reference Standard; N1-[4-nitro-3-(trifluoromethyl)phenyl]-2-methylpropanamide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide #; Flutamide, United States Pharmacopeia (USP) Reference Standard; alpha,alpha,alpha-trifluoro-2-methyl-4''-nitro-m-propionotoluidide; m-Propionotoluidide, 2-methyl-4'-nitro-.alpha.,.alpha.,.alpha.-trifluoro-; Flutamide for system suitability, European Pharmacopoeia (EP) Reference Standard; 37209-54-4Synonyme